טוען...
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
BACKGROUND: Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food and Drug Administration adverse event reporting system (FAERS). METHODS: We mined...
שמור ב:
| הוצא לאור ב: | Cardiovasc Diabetol |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7879696/ https://ncbi.nlm.nih.gov/pubmed/33573667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01243-4 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|